Page last updated: 2024-08-05 11:05:25

adamantanes

Compounds containing an adamantane skeleton.

ChEBI ID: 51339

Members (7)

MemberDefinitionRole
a 77636An isochromene that is 3,4-dihydroisochromene-5,6-diol bearing additional aminomethyl and 1-adamantyl substituents at positions 1 and 3 respectively (the 1R,3S-diastereomer). Potent and selective dopamine D1-like receptor agonist (pEC50 values are 8.97 and < 5 for D1-like and D2-like receptors respectively). Displays anti-Parkinsonian activity following oral administration in vivo.(1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol
adamantaneadamantane
adapaleneA naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether.adapalene
amantadineA member of the class of adamantanes that is used as an antiviral and antiparkinson drug.amantadine
bms 477118A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2S)-amino(3-hydroxyadamantan-1-yl)acetic acid with the amino group of (1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carbonitrile. Used in its monohydrate form for the treatment of Type II diabetes.saxagliptin
cd 437A naphthoic acid that is 6-phenylnaphthylene-2-carboxyic acid in which the phenyl substituent has been substituted at positions 3 and 4 by adamant-1-yl and hydroxy groups, respectively. It acts as a selective agonist of retinoic acid receptor (RAR)gamma and induces cell cycle arrest and apoptosis in various cancer cells.CD437
memantineA primary aliphatic amine that is the 3,5-dimethyl derivative of 1-aminoadamantane. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels.memantine

Research

Studies (9,843)

TimeframeStudies, Drugs in This Class (%)All Drugs %
pre-19901,784 (18.12)18.7374
1990's990 (10.06)18.2507
2000's2,550 (25.91)29.6817
2010's3,635 (36.93)24.3611
2020's884 (8.98)2.80

Study Types

Publication TypeStudies, Drugs in This Class (%)All Drugs (%)
Trials1,366 (12.52%)5.53%
Reviews1,475 (13.52%)6.00%
Case Studies584 (5.35%)4.05%
Observational51 (0.47%)0.25%
Other7,431 (68.13%)84.16%